PubRank

Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 31728631)

Published in Eur Arch Psychiatry Clin Neurosci on November 14, 2019

Authors

Elena Huerta-Ramos1, Javier Labad2, Jesus Cobo2, Christian Núñez3,4,5, Marta Creus6, Gemma García-Parés7, Daniel Cuadras3,4,5, José Franco6, Eva Miquel3, Julio-César Reyes6, Silvia Marcó-García3,4,5, RALOPSYCAT Group, Judith Usall3,4,8,5

Author Affiliations

1: Parc Sanitari Sant Joan de Déu, CIBERSAM G11, Barcelona, Spain. mehuerta@pssjd.org.
2: Corporació Sanitària Parc Taulí, Barcelona, Spain.
3: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42. Sant Boi de Llobregat, 08830, Barcelona, Spain.
4: Fundació Sant Joan de Déu, Barcelona, Spain.
5: Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
6: Institut Pere Mata, Tarragona, Spain.
7: Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, Andorra.
8: Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain.

Associated clinical trials:

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women | NCT01573637

Articles by these authors ⇆

Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial. Schizophr Bull (2015) 0.76

Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. JMIR Mhealth Uhealth (2016) 0.75

Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol (2016) 0.75